David Ke has dedicated nearly 30 years to the discovery and development of innovative drugs for the treatment of serious musculoskeletal diseases. David is the Founder, Chairman of the Board, and Chief Executive Officer of Angitia. Before founding Angitia in 2018, David served as Vice President and Head of Bone Therapeutic Area at UCB Pharma in the UK, Scientific Executive Director and Head of Bone Research in Amgen Inc. in the US, and Research Fellow and Head of Bone Pharmacology in Pfizer Central Research and Development in the US. As a major contributors, David led his teams to the successful discovery and development of blockbuster innovative drugs for the treatment of serious bone diseases, which have been launched in the US, Europe, Japan, China, and other parts of the world. These innovative drugs include Prolia (for osteoporosis), Xgeva (for bone metastases) and Evenity (for osteoporosis).

David’s research has focused on the disease pathophysiology of primary and secondary osteoporosis, delayed fracture healing, multiple myeloma-related bone diseases, bone tumors, muscle weakness, chronic kidney disease, osteoarthritis, and rare musculoskeletal diseases. He has published 162 peer-reviewed scientific papers and review articles with more than 12,000 citations. David was the chairman of the International Conference on Osteoporosis and Bone Research, co-organized by the Chinese Society of Osteoporosis and Bone Mineral Research and the International Bone and Mineral Society (IBMS). David is also one of the co-founders and former President of the International Chinese Musculoskeletal Research Society (ICMRS). He currently serves on the Board of Directors for the International Society of Bone Morphometry, as a consultant for the Orthopedic Branch of the Chinese Society of Gerontology and Geriatrics, and as an editorial board member of several international journals. He is also serving as a visiting professor at the University of Utah School of Medicine, the Chinese University of Hong Kong School of Medicine, and Guangdong Medical University.

Dr. Dere has extensive experience in clinical development and medical science during his 30-year career in the biopharmaceutical industry and academic institutes. Prior to joining Angitia, Dr. Dere served as Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical and Translational Science at the University of Utah Health Sciences Center. Before his appointment at the University of Utah, Dr. Dere served as Chief Medical Officer and Senior Vice President, Head of Global Clinical Development at Amgen. Before joining Amgen in 2003, Dr. Dere served as Vice President of Endocrine, Bone, and General Medicine Research and Development at Eli Lilly and Company, where he also held various leadership positions in clinical pharmacology, regulatory affairs, and both early-stage and late-stage clinical development.

Dr. Dere received an M.D. degree from the University of California, Davis, and completed his internal medicine residency training at University of Utah School of Medicine, with further training in endocrinology and metabolism at the University of California, San Francisco.

Dr. Dere serves as the CMO as well as Chief Advisor to the CEO, leading the efforts of medical and clinical development strategy.

Luna has accumulated over 15 years of experience in the healthcare industry across multinational companies (MNCs), venture capital firms, and startup companies, focusing on business development, research and clinical project management, development strategy and biotech investment.

Prior to joining Angitia, Luna was the COO of BOHE Angel Fund, where she gained extensive experience in venture capital investment and startup biotech management. Her previous roles at Novartis in early portfolio management and late-stage clinical portfolio management, and then at Roche in searching for and evaluating innovative research projects, helped her solidify a knowledge and understanding of the full development cycle of innovative drugs. Earlier in her career, Luna also served as an Investment Manager at Yuanbio Venture Capital and as a Senior Business Development Manager at PharmaLegacy.

Luna received her B.S. in Pharmaceutical Science from Shandong University, and her MBA degree from Fudan-BI Norwegian Business School, and a degree from Lancaster University in United Kingdom.

As COO of Angitia, Luna is responsible for corporate operations, talent management, finance, and corporate strategies and development.

Michael H. Arenberg joined Angitia in April 2024 as Chief Financial Officer with responsibility for all financial and capital market activities, including investor relations, accounting, financial reporting, strategic communications, strategic planning, financial planning and analysis, and additional operational responsibilities.

Prior to joining Angitia, Mr. Arenberg was Chief Operating Officer and Chief Business Officer at Imago BioSciences where he was responsible for overseeing all capital market activities, including investor relations, corporate and business development, information technology, commercial planning, and additional operational responsibilities. He led the deal process that led to the $1.35 billion acquisition of Imago by Merck in 2023

Prior to joining Imago, Mr. Arenberg was Chief Financial Officer (CFO) at Durect Corporation, a clinical stage biopharmaceutical company, where he was responsible for overseeing all financial and capital market activities, including accounting, financial reporting, financial planning and analysis, and investor relations, with additional operational responsibilities, including business and corporate development, IT, HR and strategic planning and served as Corporate Secretary.  Prior to becoming CFO, Mr. Arenberg served as Senior Vice President, Corporate and Business Development, where he negotiated and closed over 70 strategic transactions.  Prior to joining Durect, Mr. Arenberg was a co-founder of IntraEAR, Inc. a medical device start-up company that was acquired by Durect.

Mr. Arenberg earned his law degree from the University of Denver Sturm College of Law, and his M.B.A. from the Leavy School of Business at Santa Clara University.

Lei Zheng, Ph.D., has extensive experience in pharmaceutical product and process development and related technology areas. She began her career in academia, holding the position of Assistant Professor at Case Western Reserve University (CWRU) School of Medicine, before transitioning to the industry. She has held leadership positions with increasing responsibilities in globally leading pharmaceutical companies such as Abbott, Hospira, and Pfizer. Her areas of expertise include process development, quality management, technical management, and technology transfers for sterile products. Prior to joining Angitia, she held the position of Director at Pfizer Global Technical Services and Engineering, responsible for transferring a large portfolio of products from the US and EU to Asian countries.

Lei Zheng received her Ph.D. in Pharmaceutical Chemistry from CWRU in the United States and MS and BS in Chemistry from Peking University in China.

As Chief Technology Officer, Lei leads a team responsible for manufacturing process development, CMC (Chemistry, Manufacturing, and Controls), and Quality at Angitia.

Dr. Xiaofeng Liu has over 10 years of experience in drug design and discovery. He is well-versed in the discovery and optimization of various drug modality candidates. He is an expert in structure-based rational drug design and is responsible for drug screening and lead optimization of preclinical projects at Angitia. Before joining Angitia, he spent 8 years as a senior research scientist in UCB Biopharmaceutical in the UK, working on structure-based novel antibody design. Prior to UCB, he was an associate principal investigator at the School of Pharmacy, East China University of Science and Technology, working on the design of novel small molecule drugs. Xiaofeng obtained his PhD in Drug Design from Shanghai Institute of Materia Medica and completed his post-doctoral research at UCB (UK).

Dr. Zovein has over 20 years of experience in academia and biopharma, with expertise in basic science and clinical drug development. Prior to joining Angitia, Ann was an early clinical development lead and molecular genetics director at Amgen. Before Amgen, Ann led a successful research group in hematopoietic stem cell and vascular biology as a tenured Associate Professor in the Department of Pediatrics and Principal Investigator in the Cardiovascular Research Institute at the University of California, San Francisco. As part of her progress in research, Ann was awarded NIH Innovator and CIRM New Faculty Physician Scientist Awards.

Additionally, Ann served as a member of the FDA CBER's Cellular, Tissue, and Gene Therapies Advisory Committee. Trained as a physician in Neonatal Intensive Care, she obtained her medical degree from Boston University School of Medicine, and her biomedical engineering degree from Boston University College of Engineering. Due to her interest in the biotechnology industry and business development, she also earned an executive MBA from the Anderson School of Management, University of California, Los Angeles.

Dr. Ricardo E. Dent-Acosta has extensive experience in clinical development and regulatory affairs, with over 15 years in the biopharmaceutical industry and at the US Food & Drug Administration. Prior to joining Angitia, Dr. Dent-Acosta led the clinical development of various early and late-stage bone and cardiometabolic products at both Amgen and Esperion Therapeutics, with increasing roles and responsibilities from Medical Director to Vice President. Before his entry into industry, Dr. Dent-Acosta served as a clinical reviewer for oncology products at the CBER Office of Cellular, Tissue, and Gene Therapy, and for pain and addiction products at the CDER Division of Anesthesia, Analgesia, and Rheumatology Products.

Dr. Dent-Acosta completed his medical training at the University of Puerto Rico School of Medicine in San Juan, Puerto Rico, and completed his residency training in Internal Medicine and Pediatrics at Louisiana State University Health Sciences Center in Shreveport, Louisiana.

Tom has over 19 years of experience in business development and strategy in large- and mid-cap biopharmaceutical companies. He has held roles of increasing responsibility at Exelixis, Jazz Pharmaceuticals, and Amgen. He has closed transactions across a broad range of deal type, complexity, and strategic intent. While at Amgen, Tom led strategy and business development initiatives relating to Amgen’s blockbuster musculoskeletal products, Prolia and Evenity. Tom also led the product development team at Jazz Pharmaceuticals, advancing a first-in-class small molecule drug in phase 2 development.

Tom holds a Bachelor of Arts from Whitman College, a Master of Bioscience from Keck Graduate Institute of Applied Life Sciences, and a Master of Business Administration from UCLA Anderson School of Management.